Literature DB >> 9862414

Selective inhibition of NF-kappaB activation by the flavonoid hepatoprotector silymarin in HepG2. Evidence for different activating pathways.

C Saliou1, B Rihn, J Cillard, T Okamoto, L Packer.   

Abstract

The bioflavonoid silymarin is found to potently suppress both nuclear factor kappa-B (NF-kappaB)-DNA binding activity and its dependent gene expression induced by okadaic acid in the hepatoma cell line HepG2. Surprisingly, tumor necrosis factor-alpha-induced NF-kappaB activation was not affected by silymarin, thus demonstrating a pathway-dependent inhibition by silymarin. Many genes encoding the proteins of the hepatic acute phase response are under the control of the transcription factor NF-kappaB, a key regulator in the inflammatory and immune reactions. Thus, the inhibitory effect of silymarin on NF-kappaB activation could be involved in its hepatoprotective property.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9862414     DOI: 10.1016/s0014-5793(98)01409-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  17 in total

Review 1.  The use of selected nutrition supplements and complementary and alternative medicine in liver disease.

Authors:  A James Hanje; Brett Fortune; Ming Song; Daniell Hill; Craig McClain
Journal:  Nutr Clin Pract       Date:  2006-06       Impact factor: 3.080

Review 2.  The use of silymarin in the treatment of liver diseases.

Authors:  R Saller; R Meier; R Brignoli
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Aldo-keto reductase 1 family B7 is the gene induced in response to oxidative stress in the livers of Long-Evans Cinnamon rats.

Authors:  Guang Jia; Ryoya Takahashi; Zhiping Zhang; Yoshiaki Tsuji; Hideko Sone
Journal:  Int J Oncol       Date:  2006-10       Impact factor: 5.650

Review 4.  Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Authors:  Tomas Koltai; Larry Fliegel
Journal:  J Evid Based Integr Med       Date:  2022 Jan-Dec

5.  Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators.

Authors:  Samiha Mateen; Alpna Tyagi; Chapla Agarwal; Rana P Singh; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2010-03       Impact factor: 4.784

Review 6.  Cocoa, chocolate, and cardiovascular disease.

Authors:  Monica Galleano; Patricia I Oteiza; Cesar G Fraga
Journal:  J Cardiovasc Pharmacol       Date:  2009-12       Impact factor: 3.105

7.  In vitro mechanistic studies on α-amanitin and its putative antidotes.

Authors:  Daniela Ferreira Rodrigues; Ricardo Pires das Neves; Alexandra T P Carvalho; Maria Lourdes Bastos; Vera M Costa; Félix Carvalho
Journal:  Arch Toxicol       Date:  2020-03-19       Impact factor: 5.153

Review 8.  Polyphenols and gastrointestinal diseases.

Authors:  Gerald W Dryden; Ming Song; Craig McClain
Journal:  Curr Opin Gastroenterol       Date:  2006-03       Impact factor: 3.287

9.  Inhibition of TNFalpha-induced cyclooxygenase-2 expression by amentoflavone through suppression of NF-kappaB activation in A549 cells.

Authors:  Tinku Banerjee; Giuseppe Valacchi; Vincent A Ziboh; Albert van der Vliet
Journal:  Mol Cell Biochem       Date:  2002-09       Impact factor: 3.396

10.  Silymarin nanoparticle prevents paracetamol-induced hepatotoxicity.

Authors:  Suvadra Das; Partha Roy; Runa Ghosh Auddy; Arup Mukherjee
Journal:  Int J Nanomedicine       Date:  2011-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.